Scilex Issues Warrants to Oramed for Debt Payment Deferral

summarizeSummary

Scilex Holding Co. issued warrants to Oramed Pharmaceuticals Inc. to purchase 100,000 common shares at a $20.00 exercise price, as consideration for deferring a debt amortization payment.

check_boxKey Events

• Warrant Issuance for Debt Deferral

  Scilex issued warrants to Oramed Pharmaceuticals Inc. to purchase 100,000 shares of common stock. This was in exchange for Oramed deferring an amortization payment on a Senior Secured Convertible Note, which was due October 1, 2025, and subsequently paid in November 2025.

• Warrant Terms

  The warrants have an initial exercise price of $20.00 per share and expire on December 13, 2029. The exercise price is subject to anti-dilution adjustments, with a floor price of $8.22 per share.

• Future Dilution Potential

  If exercised, these warrants could lead to the issuance of 100,000 new common shares, representing a notable potential dilution relative to the company's market capitalization, although they are currently out-of-the-money.

• Registration Commitment

  Scilex has agreed to file a registration statement (Form S-3 or S-1) to allow for the resale of the common shares underlying these warrants.

auto_awesomeAnalysis

This 8-K details a material definitive agreement where Scilex issued warrants to Oramed Pharmaceuticals Inc. The warrants, exercisable for 100,000 common shares at a $20.00 strike price, were compensation for Oramed deferring an amortization payment on a Senior Secured Convertible Note, which was due October 1, 2025, and subsequently paid in November 2025. While the warrants are currently out-of-the-money compared to the current stock price of $8.12, they represent potential future dilution if the stock price appreciates. The agreement includes anti-dilution provisions with a floor price of $8.22, protecting the warrant holder in case of future dilutive offerings. This transaction reflects the company's ongoing efforts to manage its financial obligations and capital structure, following recent significant financial activities such as a strategic investment and prior stock sales by a 10% owner.